Brief: Mesoblast Updates On Option To Issue Up To $50M Convertible Notes
Sept 30 (Reuters) - Mesoblast Ltd MSB.AX :
* MESOBLAST OPTION TO ISSUE UP TO US$50M CONVERTIBLE NOTES
* TO ISSUE CONVERTIBLE NOTES IN TRANCHES OF US$10 MILLION AT
ANY
TIME FOLLOWING AN FDA APPROVAL OF RYONCIL FOR A 90-DAY PERIOD
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M